Scarica l'app Stockscreener
268.80
0.57%
1.52
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
(PRAX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Praxis Precision Medicines Plans New Drug Application - The Globe and Mail
Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 - Yahoo Finance
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating - marketscreener.com
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Praxis Precision Medicines updates clinical trial design and regulatory plans - Investing.com
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - MSN
Praxis Precision Medicines Confirms FDA Filing Path for New Drug Application of Relutrigine in Early 2026 - Quiver Quantitative
TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 - Yahoo Finance
TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment - Insider Monkey
HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN
Stempoint Capital LP Takes $1.36 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus
Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative
Praxis Precision Medicines announces alignment with FDA - marketscreener.com
PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus
Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Eastern Progress
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive - ts2.tech
Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Swiss National Bank - MarketBeat
Praxis Precision Medicine (PRAX): Guggenheim Raises Price Target to $760 | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Praxis Precision Medicines, Inc. $PRAX Stock Holdings Boosted by B Group Inc. - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins - Insider Monkey
BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
PRAX Stock Surge: Rally or Risk? - StocksToTrade
Praxis Precision Medicines reports clinical updates on epilepsy drug candidates - Investing.com Nigeria
Praxis Precision Medicines Shares RADIANT Study Results - TipRanks
TD Cowen Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $353.00 - MarketBeat
TD Cowen Raises Price Target for PRAX to $353, Maintains Buy Rat - GuruFocus
Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen - Investing.com Nigeria
Truist Securities Raises Price Target for PRAX to $500 | PRAX St - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Given New $500.00 Price Target at Truist Financial - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat
Needham raises Praxis Precision Medicines stock price target on improved data - Investing.com Nigeria
Truist Securities raises Praxis Precision Medicines stock price target to $500 - Investing.com Nigeria
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data By Investing.com - Investing.com South Africa
PRAX Releases Promising Clinical Updates on Epilepsy Treatments - GuruFocus
Praxis Precision Medicine (PRAX) Sees Raised Price Target by Nee - GuruFocus
Needham & Company LLC Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Praxis Precision Medicines Reports Positive EMBOLD and RADIANT Study Results for Relutrigine and Vormatrigine in Epilepsy Treatment - Quiver Quantitative
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies - The Manila Times
Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating - marketscreener.com
HC Wainwright Reiterates 'Buy' Rating on PRAX with $340 PT | PRA - GuruFocus
Praxis (NASDAQ: PRAX) posts 53% seizure drop in EMBOLD trial, plans FDA NDA talks - Stock Titan
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data - Investing.com Australia
BTIG Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX: BTIG Raises Price Target to $507 with Buy Rating | PRAX St - GuruFocus
Praxis Precision Medicines (PRAX) Gaining Confidence on EMBOLD Study Optimism - Insider Monkey
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):